melatonin has been researched along with Polycystic Ovarian Syndrome in 36 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effect of melatonin supplementation on mental health parameters, metabolic and genetic parameters in women suffering from polycystic ovary syndrome (PCOS)." | 9.30 | Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. ( Aghadavod, E; Asemi, Z; Eftekhar, T; Foroozanfard, F; Kavossian, E; Ostadmohammadi, V; Reiter, RJ; Shabani, A, 2019) |
| "The objective of the present study was to investigate the effect of melatonin and L-thyroxine (T4) on the expression of various receptors, and some metabolic, reproductive, and gonadotropic hormones in letrozole-induced polycystic ovary syndrome (PCOS) in rats." | 8.12 | Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome. ( Brown, GM; Cardinali, DP; Ghosh, H; Manzar, MD; Pandi-Perumal, SR; Rai, S; Reiter, RJ, 2022) |
| "This study was undertaken to study the effects of melatonin on metabolic and reproductive aspects of polycystic ovary syndrome (PCOS) in rats." | 7.80 | Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats. ( Majumdar, AS; Pai, SA, 2014) |
| "The current study was conducted to investigate the relationship between melatonin and chronic anovulation." | 7.72 | Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome. ( Baracat, EC; Prata Lima, MF; Simões, MJ, 2004) |
| "Melatonin is a neurohormone synthesized from the aromatic amino acid tryptophan mainly by the pineal gland of mammals." | 6.58 | Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. ( Gu, CJ; Li, DJ; Li, MQ; Meng, YH; Shao, J; Yang, HL; Zhou, WJ, 2018) |
| "Melatonin was found to be effective via the MT1 receptor in the pathogenesis of PCOS, and it suppressed the transport pathways of GDF9 to granulosa cells in antral follicles." | 5.91 | Melatonin effective to reduce the microscopic symptoms of polycystic ovary syndrome-related infertility: An experimental study. ( Arık, GN; Dinçel, AS; Elmazoğlu, Z; Kaplanoğlu, GT; Sağlam, ASY; Seymen, CM, 2023) |
| "Letrozole was administered orally (1 mg kg-1) to induce PCOS condition in Wistar female rats for a period of 2-3 weeks followed by a dose of melatonin (200 µg/100 g b." | 5.48 | Therapeutic Efficacy of Melatonin Against Polycystic Ovary Syndrome (PCOS) Induced by Letrozole in Wistar Rat. ( Ahmad Hajam, Y; Basheer, M; Ghosh, H; Rai, S, 2018) |
| "The aim of this study was to evaluate the effect of melatonin supplementation on mental health parameters, metabolic and genetic parameters in women suffering from polycystic ovary syndrome (PCOS)." | 5.30 | Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. ( Aghadavod, E; Asemi, Z; Eftekhar, T; Foroozanfard, F; Kavossian, E; Ostadmohammadi, V; Reiter, RJ; Shabani, A, 2019) |
| "The objective of the present study was to investigate the effect of melatonin and L-thyroxine (T4) on the expression of various receptors, and some metabolic, reproductive, and gonadotropic hormones in letrozole-induced polycystic ovary syndrome (PCOS) in rats." | 4.12 | Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome. ( Brown, GM; Cardinali, DP; Ghosh, H; Manzar, MD; Pandi-Perumal, SR; Rai, S; Reiter, RJ, 2022) |
| "The objective of the study was to investigate the effects of 6 months of melatonin administration on clinical, endocrine, and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 3.88 | Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. ( Apa, R; Cicco, S; Florio, CD; Immediata, V; Lanzone, A; Romualdi, D; Santarsiero, CM; Scarinci, E; Tagliaferri, V; Tropea, A, 2018) |
| "This study was undertaken to study the effects of melatonin on metabolic and reproductive aspects of polycystic ovary syndrome (PCOS) in rats." | 3.80 | Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats. ( Majumdar, AS; Pai, SA, 2014) |
| " However, there have been few studies examining the possible association between melatonin levels and sleep quality in women with polycystic ovarian syndrome (PCOS)." | 3.79 | Poor sleep in PCOS; is melatonin the culprit? ( Brook, N; Cagampang, F; Cheong, Y; Hill, CM; Houldey, A; Macklon, N; Sadek, K; Shreeve, N; Tolhurst, M, 2013) |
| "The current study was conducted to investigate the relationship between melatonin and chronic anovulation." | 3.72 | Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome. ( Baracat, EC; Prata Lima, MF; Simões, MJ, 2004) |
| "Metformin is a safe medication used in PCOS for 25 years that is currently recommended in select PCOS subpopulations, such as adolescents, women with metabolic disorders, and infertility infertile women undergoing ovarian hyperstimulation." | 2.61 | Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome. ( Banaszewska, B; Pawelczyk, L; Spaczynski, R, 2019) |
| "Melatonin is a neurohormone synthesized from the aromatic amino acid tryptophan mainly by the pineal gland of mammals." | 2.58 | Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. ( Gu, CJ; Li, DJ; Li, MQ; Meng, YH; Shao, J; Yang, HL; Zhou, WJ, 2018) |
| "Despite current treatments for polycystic ovary syndrome (PCOS), a considerable number of women with this syndrome do not reach the treatment goal, suggesting the presence of other probable misdiagnosed features of this syndrome that are not taken into account in the assessment and therefore in the therapeutical approach." | 1.91 | Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome. ( Barrea, L; Colao, A; de Alteriis, G; Docimo, A; Muscogiuri, G; Savastano, S; Verde, L; Vetrani, C, 2023) |
| "Melatonin was found to be effective via the MT1 receptor in the pathogenesis of PCOS, and it suppressed the transport pathways of GDF9 to granulosa cells in antral follicles." | 1.91 | Melatonin effective to reduce the microscopic symptoms of polycystic ovary syndrome-related infertility: An experimental study. ( Arık, GN; Dinçel, AS; Elmazoğlu, Z; Kaplanoğlu, GT; Sağlam, ASY; Seymen, CM, 2023) |
| "Melatonin treatment decreased mitochondrial permeability transition pore (mPTP) opening and increased the JC-1 (5,5',6,6'-tetrachloro1,1',3,3'-tetramethylbenzimidazolylcarbocyanine iodide) aggregate/monomer ratio in the live KGN cells treated with DHT, indicating melatonin mediates mPTP to increase mitochondrial membrane potential." | 1.62 | Melatonin enhances SIRT1 to ameliorate mitochondrial membrane damage by activating PDK1/Akt in granulosa cells of PCOS. ( Ding, M; Meng, J; Zhang, Y; Zheng, B; Zhou, J; Zhu, Y, 2021) |
| "Letrozole was administered orally (1 mg kg-1) to induce PCOS condition in Wistar female rats for a period of 2-3 weeks followed by a dose of melatonin (200 µg/100 g b." | 1.48 | Therapeutic Efficacy of Melatonin Against Polycystic Ovary Syndrome (PCOS) Induced by Letrozole in Wistar Rat. ( Ahmad Hajam, Y; Basheer, M; Ghosh, H; Rai, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 14 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Ghosh, H | 2 |
| Rai, S | 2 |
| Manzar, MD | 1 |
| Pandi-Perumal, SR | 1 |
| Brown, GM | 1 |
| Reiter, RJ | 2 |
| Cardinali, DP | 1 |
| Zheng, B | 1 |
| Meng, J | 1 |
| Zhu, Y | 2 |
| Ding, M | 1 |
| Zhang, Y | 1 |
| Zhou, J | 2 |
| Guo, R | 1 |
| Zheng, H | 1 |
| Li, Q | 1 |
| Qiu, X | 1 |
| Zhang, J | 3 |
| Cheng, Z | 1 |
| Nikmard, F | 1 |
| Hosseini, E | 1 |
| Bakhtiyari, M | 1 |
| Ashrafi, M | 1 |
| Amidi, F | 1 |
| Aflatoonian, R | 1 |
| Li, H | 1 |
| Liu, M | 1 |
| Zhang, C | 1 |
| Barrea, L | 3 |
| Verde, L | 3 |
| Vetrani, C | 3 |
| Docimo, A | 3 |
| de Alteriis, G | 3 |
| Savastano, S | 3 |
| Colao, A | 3 |
| Muscogiuri, G | 3 |
| Arık, GN | 2 |
| Kaplanoğlu, GT | 1 |
| Sağlam, ASY | 1 |
| Elmazoğlu, Z | 2 |
| Dinçel, AS | 1 |
| Seymen, CM | 2 |
| Kılınç Uğurlu, A | 1 |
| Bideci, A | 1 |
| Demirel, MA | 1 |
| Take Kaplanoğlu, G | 2 |
| Dayanır, D | 1 |
| Gülbahar, Ö | 1 |
| Deveci Bulut, TS | 1 |
| Döğer, E | 1 |
| Çamurdan, MO | 1 |
| Banaszewska, B | 1 |
| Pawelczyk, L | 1 |
| Spaczynski, R | 1 |
| Yu, K | 1 |
| Wang, RX | 1 |
| Li, MH | 1 |
| Sun, TC | 1 |
| Zhou, YW | 1 |
| Li, YY | 1 |
| Sun, LH | 1 |
| Zhang, BL | 1 |
| Lian, ZX | 1 |
| Xue, SG | 1 |
| Liu, YX | 1 |
| Deng, SL | 1 |
| Wang, F | 1 |
| Xie, N | 1 |
| Wu, Y | 1 |
| Zhang, Q | 1 |
| Dai, M | 1 |
| Pan, J | 1 |
| Tang, M | 1 |
| Cheng, Q | 1 |
| Shi, B | 1 |
| Guo, Q | 1 |
| Li, X | 1 |
| Xie, L | 1 |
| Wang, B | 1 |
| Yang, D | 1 |
| Weng, Q | 1 |
| Guo, L | 1 |
| Ye, J | 1 |
| Pan, M | 1 |
| Zhang, S | 1 |
| Zhou, H | 1 |
| Zhen, C | 1 |
| Liu, P | 1 |
| Ning, K | 1 |
| Brackenridge, L | 1 |
| Hardiman, PJ | 1 |
| Qu, F | 1 |
| Xie, F | 1 |
| Zhai, M | 1 |
| Liu, Y | 2 |
| Hu, H | 1 |
| Yu, Z | 1 |
| Lin, S | 1 |
| Liang, D | 1 |
| Cao, Y | 1 |
| Mousavi, R | 1 |
| Alizadeh, M | 1 |
| Asghari Jafarabadi, M | 1 |
| Heidari, L | 1 |
| Nikbakht, R | 1 |
| Babaahmadi Rezaei, H | 1 |
| Karandish, M | 1 |
| Hansda, SR | 1 |
| Haldar, C | 1 |
| Jiang, Y | 1 |
| Shi, H | 1 |
| Zhao, S | 1 |
| Zhao, H | 1 |
| Yar Sağlam, AS | 1 |
| Tagliaferri, V | 1 |
| Romualdi, D | 1 |
| Scarinci, E | 1 |
| Cicco, S | 1 |
| Florio, CD | 1 |
| Immediata, V | 1 |
| Tropea, A | 1 |
| Santarsiero, CM | 1 |
| Lanzone, A | 1 |
| Apa, R | 1 |
| Yang, HL | 1 |
| Zhou, WJ | 1 |
| Gu, CJ | 1 |
| Meng, YH | 1 |
| Shao, J | 1 |
| Li, DJ | 1 |
| Li, MQ | 1 |
| Basheer, M | 1 |
| Ahmad Hajam, Y | 1 |
| Showell, MG | 1 |
| Mackenzie-Proctor, R | 1 |
| Jordan, V | 1 |
| Hodgson, R | 1 |
| Farquhar, C | 1 |
| Shabani, A | 1 |
| Foroozanfard, F | 1 |
| Kavossian, E | 1 |
| Aghadavod, E | 1 |
| Ostadmohammadi, V | 1 |
| Eftekhar, T | 1 |
| Asemi, Z | 1 |
| Simon, SL | 1 |
| McWhirter, L | 1 |
| Diniz Behn, C | 1 |
| Bubar, KM | 1 |
| Kaar, JL | 1 |
| Pyle, L | 1 |
| Rahat, H | 1 |
| Garcia-Reyes, Y | 1 |
| Carreau, AM | 1 |
| Wright, KP | 1 |
| Nadeau, KJ | 1 |
| Cree-Green, M | 1 |
| Lombardi, LA | 1 |
| Mattos, LS | 1 |
| Simões, RS | 1 |
| Florencio-Silva, R | 1 |
| Sasso, GRDS | 1 |
| Carbonel, AAF | 1 |
| Simões, MJ | 2 |
| Baracat, EC | 2 |
| Soares, JM | 1 |
| Shreeve, N | 2 |
| Cagampang, F | 1 |
| Sadek, K | 1 |
| Tolhurst, M | 1 |
| Houldey, A | 1 |
| Hill, CM | 1 |
| Brook, N | 1 |
| Macklon, N | 1 |
| Cheong, Y | 1 |
| Kawada, T | 1 |
| Lemos, AJ | 1 |
| Peixoto, CA | 1 |
| Teixeira, AA | 1 |
| Luna, RL | 1 |
| Rocha, SW | 1 |
| Santos, HM | 1 |
| Silva, AK | 1 |
| Nunes, AK | 1 |
| Wanderley-Teixeira, V | 1 |
| Pai, SA | 1 |
| Majumdar, AS | 1 |
| Pacchiarotti, A | 2 |
| Carlomagno, G | 1 |
| Antonini, G | 1 |
| Kim, MK | 1 |
| Park, EA | 1 |
| Kim, HJ | 1 |
| Choi, WY | 1 |
| Cho, JH | 1 |
| Lee, WS | 1 |
| Cha, KY | 1 |
| Kim, YS | 1 |
| Lee, DR | 1 |
| Yoon, TK | 1 |
| Luboshitzky, R | 3 |
| Shen-Orr, Z | 3 |
| Herer, P | 2 |
| Nave, R | 1 |
| Prata Lima, MF | 1 |
| Tarquini, R | 1 |
| Bruni, V | 1 |
| Perfetto, F | 1 |
| Bigozzi, L | 1 |
| Tapparini, L | 1 |
| Tarquini, B | 1 |
| Qupti, G | 1 |
| Ishay, A | 1 |
| Futerman, B | 1 |
| Linn, S | 1 |
| Cagnacci, A | 1 |
| Volpe, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls[NCT02157974] | Phase 2/Phase 3 | 92 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Investigating the Relationship Between Circadian Phase and Insulin Resistance in Obese Adolescents[NCT02585830] | 25 participants (Actual) | Observational | 2015-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
~1mL saliva was collected at 30- to 60- minute intervals in dim light (<5 lux in the angle of gaze, approximately the light level of candlelight or civil twilight) from approximately 5pm until noon the next day. Dim light melatonin onset (DLMOn) was defined as the linear interpolated clock time at which evening salivary melatonin concentrations increased and remained above a threshold of 3pg/mL. Melatonin offset (DLMOff) was the linear interpolated clock time at which salivary melatonin concentrations fell below this threshold. Later DLMOn and DLMOff are indicative of a later circadian rhythm. (NCT02585830)
Timeframe: 1 day
| Intervention | decimal hours (Mean) | |
|---|---|---|
| Dim Light Melatonin Onset | Dim Light Melatonin Offset | |
| Observation | 21.33 | 8.32 |
After an overnight fast, participants completed an oral glucose tolerance test (OGTT) in the morning. Participants consumed a 75g dextrose drink and serum for glucose and insulin concentrations were collected at baseline and every 30 minutes for 3 hours. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as [fasting insulin (μU/ml) x fasting glucose (mmol/l)] / 22.5); lower HOMA-IR indicates better insulin sensitivity. The Matsuda Index was calculated as √10,000 / [[fasting insulin (μU/ml) x fasting glucose (mmol/l)] x [mean OSTT insulin (μU/ml) x mean OSTT glucose (mmol/l)]]; high Matsuda Index indicates better insulin sensitivity. (NCT02585830)
Timeframe: 3 hours
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Homeostatic Model Assessment (HOMA-IR) | Matsuda Index | |
| Observation | 2.9 | 4.93 |
4 reviews available for melatonin and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome.
Topics: Antioxidants; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; I | 2019 |
Applications of Melatonin in Female Reproduction in the Context of Oxidative Stress.
Topics: Animals; Female; Humans; Infertility, Female; Melatonin; Oxidative Stress; Polycystic Ovary Syndrome | 2021 |
Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome.
Topics: Abortion, Habitual; Abortion, Spontaneous; Animals; Endometriosis; Female; Humans; Melatonin; Polycy | 2018 |
Inositol for subfertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Birth Rate; Clomiphene; Combined Modality Therapy; Fema | 2018 |
5 trials available for melatonin and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adolescent; Adult; Biomarkers; Dietary Supplements; Double-Blind Method; Female; Humans; Inflammatio | 2022 |
Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Dietary Supplements; Double-Blind Method; Female; Gene Expression; | 2019 |
Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome.
Topics: Adult; Antioxidants; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Embryo Tra | 2016 |
Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS?
Topics: Adult; Culture Media; Embryo Implantation; Enzyme-Linked Immunosorbent Assay; Female; Fertilization | 2013 |
Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Dehydroepiandrosterone Sulfate; Estradiol; Female; F | 2001 |
27 other studies available for melatonin and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome.
Topics: Animals; Disease Models, Animal; Estrogen Receptor alpha; Female; Gene Expression; Gene Expression R | 2022 |
Melatonin enhances SIRT1 to ameliorate mitochondrial membrane damage by activating PDK1/Akt in granulosa cells of PCOS.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adult; Animals; bcl-2-Associated X Protein; Benzimidaz | 2021 |
Melatonin alleviates insulin resistance through the PI3K/AKT signaling pathway in ovary granulosa cells of polycystic ovary syndrome.
Topics: Female; Granulosa Cells; Humans; Insulin Resistance; Melatonin; Phosphatidylinositol 3-Kinases; Poly | 2022 |
The boosting effects of melatonin on the expression of related genes to oocyte maturation and antioxidant pathways: a polycystic ovary syndrome- mouse model.
Topics: Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Bone Morphogenetic Protein 15; Dehydro | 2022 |
Women with polycystic ovary syndrome (PCOS) have reduced melatonin concentrations in their follicles and have mild sleep disturbances.
Topics: Female; Fertilization in Vitro; Follicular Fluid; Humans; Melatonin; Polycystic Ovary Syndrome; Preg | 2022 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Melatonin effective to reduce the microscopic symptoms of polycystic ovary syndrome-related infertility: An experimental study.
Topics: Animals; Female; Humans; Infertility; Melatonin; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawl | 2023 |
Effects of Blue Light on Puberty and Ovary in Female Rats
Topics: Animals; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Humans; Leptin; Lu | 2023 |
Melatonin Reduces Androgen Production and Upregulates Heme Oxygenase-1 Expression in Granulosa Cells from PCOS Patients with Hypoestrogenia and Hyperandrogenia.
Topics: Adult; Androgens; Antioxidants; Estrogens; Female; Granulosa Cells; Heme Oxygenase-1; Humans; Hypera | 2019 |
Association between circadian rhythm disruption and polycystic ovary syndrome.
Topics: Adult; Animals; Animals, Newborn; Chronobiology Disorders; Circadian Rhythm; Female; Granulosa Cells | 2021 |
Melatonin ameliorates ovarian dysfunction by regulating autophagy in PCOS via the PI3K-Akt pathway.
Topics: Adult; Animals; Antioxidants; Autophagy; Case-Control Studies; Female; Gene Expression Regulation; H | 2021 |
Uterine anomalies in cell proliferation, energy homeostasis and oxidative stress in PCOS hamsters, M. auratus: Therapeutic potentials of melatonin.
Topics: Animals; Aromatase Inhibitors; Blood Glucose; Cell Proliferation; Cricetinae; Disease Models, Animal | 2021 |
Involvement of endometrial IGF-1R/IGF-1/Bcl-2 pathways in experimental polycystic ovary syndrome: Identification of the regulatory effect of melatonin.
Topics: Animals; Body Weight; Endometrium; Female; Insulin-Like Growth Factor I; Melatonin; Ovary; Polycysti | 2021 |
Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Blood Glucose; Female; Glucose Tolerance Test; Hirsutism; Human | 2018 |
Therapeutic Efficacy of Melatonin Against Polycystic Ovary Syndrome (PCOS) Induced by Letrozole in Wistar Rat.
Topics: Administration, Oral; Animals; Disease Models, Animal; Estrogens; Female; Letrozole; Melatonin; Poly | 2018 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Melatonin may prevent or reverse polycystic ovary syndrome in rats.
Topics: Animals; Estrus; Female; Immunohistochemistry; Melatonin; Polycystic Ovary Syndrome; Prospective Stu | 2019 |
Poor sleep in PCOS; is melatonin the culprit?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adolescent; Adult; Case-Control Studies; Deoxyguanosine; Female; Hormon | 2013 |
Sleep efficiency in patients with polycystic ovarian syndrome.
Topics: Female; Humans; Melatonin; Polycystic Ovary Syndrome; Sleep; Sleep Wake Disorders | 2013 |
Reply: sleep efficiency in patients with polycystic ovarian syndrome.
Topics: Female; Humans; Melatonin; Polycystic Ovary Syndrome; Sleep; Sleep Wake Disorders | 2013 |
Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome.
Topics: Animals; Antioxidants; Drug Therapy, Combination; Female; Liver; Melatonin; Metformin; Oxidative Str | 2014 |
Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats.
Topics: Animals; Disease Models, Animal; Female; Glucose Tolerance Test; Insulin Resistance; Lipid Metabolis | 2014 |
Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment.
Topics: Adolescent; Adrenocortical Hyperfunction; Adult; Androgen Antagonists; Cyproterone Acetate; Drug The | 2003 |
Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
Topics: Adrenal Hyperplasia, Congenital; Adult; Androgen Antagonists; Case-Control Studies; Cyproterone Acet | 2004 |
Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome.
Topics: Animals; Anovulation; Chronic Disease; Female; Light; Melatonin; Ovariectomy; Ovary; Pineal Gland; P | 2004 |
Hypermelatoninemia in women with polycystic ovarian syndrome.
Topics: Adult; Case-Control Studies; Circadian Rhythm; Female; Humans; Melatonin; Polycystic Ovary Syndrome | 1996 |
A role for melatonin in PCOS?
Topics: Female; Humans; Melatonin; Polycystic Ovary Syndrome | 2002 |